Advanced search
Publication Cover
Expert Review of Hematology Volume 17, 2024 - Issue 6
Submit an article Journal homepage
1,995
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma

Donald C. Moorea Department of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USACorrespondence[email protected]
View further author information
,
Katelynn Grangerb Hollings Cancer Center, Department of Pharmacy, The Medical University of South Carolina, Charleston, SC, USAView further author information
,
Hailey Hilla Department of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USAView further author information
,
Allison Karabinosa Department of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USAORCID Iconhttps://orcid.org/0000-0003-2091-0071View further author information
ORCID Icon &
James A. Davisb Hollings Cancer Center, Department of Pharmacy, The Medical University of South Carolina, Charleston, SC, USAORCID Iconhttps://orcid.org/0000-0001-7978-1652View further author information
ORCID Icon
Pages 197-200 | Received 22 Dec 2023, Accepted 07 May 2024, Published online: 11 May 2024

References

  • Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):1–7. doi: 10.1016/j.clml.2019.09.621
  • Davis JA, Shockley A, Hashmi H. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. J Oncol Pharm Pract. 2022 Jun;28(4):960–968. doi: 10.1177/10781552211073517
  • Davis J, McGann M, Shockley A, et al. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma. Expert Rev Hematol. 2022 Jun;15(6):473–475. doi: 10.1080/17474086.2022.2081147
  • Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep;29(9):2259–2267. doi: 10.1038/s41591-023-02528-9
  • Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495–505. doi: 10.1056/NEJMoa2203478
  • Granger K, Gaffney KJ, Davis JA. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. J Oncol Pharm Pract. 2023;29(3):722–726. doi: 10.1177/10781552231154809
  • Tomasson M, Iida S, Niesvizky R, et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 magneismm-3 tiral in relapsed or refractory multiple myeloa (RRMM). Blood. 2023;142(Supplement 1):3385. doi: 10.1182/blood-2023-182130
  • Elrexfio (elranatamab) [prescribing information]. New York (NY): Pfizer Inc. 2023 Aug.
  • Van de Donk N, Moreau P, Garfall A, et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16):8011. doi: 10.1200/JCO.2023.41.16_suppl.8011
  • Tecvayli (teclistamab) [prescribing information]. Horsham (PA): Janssen Biotech Inc. 2024 Feb.
  • Ahmed N, Shahzad M, Shippey E, et al. Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T cell therapy access. Transplant Cell Ther. 2022;28(7):358–364. doi: 10.1016/j.jtct.2022.04.008
  • Blade J, Beksac M, Caers J, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022 Mar 21;12(3):45. doi: 10.1038/s41408-022-00643-3
  • Dima D, Davis JA, Ahmed N, et al. Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma. Blood. 2023;12(Supplement 1):91. doi: 10.1182/blood-2023-180421
  • Dima D, Sannareddy A, Ahmed N, et al. Toxicity and efficacy outcomes of teclistamab in patients with relapsed-refractory multiple myeloma (RRMM) above the age of 70 years: a multicenter study. Blood. 2023;142(Supplement 1):3330. doi: 10.1182/blood-2023-180458
  • Sandahl TB, Soefje SA, Calay ES, et al. Real-world treatment outcomes of teclistamab under an outpatient model for step-up dosing administration. Blood. 2023;142(Supplement 1):5154. doi: 10.1182/blood-2023-174270
  • Talvey (talquetamab) [prescribing information]. Horsham (PA): Janssen Biotech, Inc. 2023 Aug.
  • Bansal R, Paludo J, Corraes A, et al. Outpatient management of CAR-T and teclistamab for patients with lymphoma and multiple myeloma. Blood. 2023;142(Supplement 1):253. doi: 10.1182/blood-2023-187186

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.